Effects of Autogenic Drainage and Flutter Device in COPD
2026年7月17日 更新者：Riphah International University
Comparative Effects of Autogenic Drainage and Flutter Device on Dyspnea, Pulmonary Function Test and Functional Capacity in COPD
COPD is a progressive lung disease that includes emphysema and chronic bronchitis and is a major cause of morbidity and mortality worldwide.
Airway clearance techniques help improve mucus removal, reduce dyspnea, and enhance quality of life in COPD patients.
This study aims to compare the effects of autogenic drainage and flutter device on dyspnea, pulmonary function, and functional capacity in patients with COPD.
A randomized clinical trial will be conducted at Gulab Devi Teaching Hospital using convenient sampling.
Participants will be divided into two groups: Group A will receive autogenic drainage, while Group B will use the flutter device.
Interventions will be performed daily for 20-30 minutes over 6 weeks.
Outcome measures will include dyspnea severity scale, spirometry, and 6-minute walk test.
Data will be analyzed using SPSS with significance set at p < 0.05.
The study may provide evidence for effective, non-invasive, and cost-effective management strategies for COPD patients.
研究概览
详细说明
Chronic obstructive pulmonary disease is progressive damage to lungs with a combination of airway diseases that are emphysema and chronic bronchitis.
COPD is the major cause of chronic mortality and morbidity throughout the world.
It's third leading cause of death in the world.
Non pharmacological intervention Airway clearance techniques plays crucial role in managing COPD and enhancing patients quality of life by removal of bronchial secretions.
Two popular techniques autogenic drainage and flutter are based on the same principle of mobilization and removal of secretions.
These non-invasive techniques aimed at enhancing mucus clearance and reducing dyspnea.
The objective of the study's primary goal is to compare the effect of autogenic drainage and flutter device on the dyspnea, pulmonary function test and functional capacity in the patients with COPD.
The study design will be ramdomized clinical trial.
It will be conducted at Ghulab Devi |Teaching Hospital.
Sample size will be conducted through non- probability convenient sampling as per inclusion criteria.
Participants will be randomly added into two groups.
Group A will receive autogenic drainage intervention and the Group B will receive flutter device intervention.
Both interventions will be practiced daily for 5 days 6 weeks for 20-30 minutes.
Pre and post intervention data will be collected.
Outcome measures include dyspnea severity scale, spirometer and 6-minute walk test.
Data will be analyzed by using SPSS.
Data will be tested for normality distribution.
Paired or Independent t-test will be used to compare variables between the two groups and within the two groups, with significance set at p< 0.05.
This study will provide evidence for the integration of non-invasive, cost effective strategies for the enhancement of PFT's and functional capacity and dyspnea.
研究类型
介入性
注册 (估计的)
42
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Muhammad Iqbal Tariq Tariq, Phd*
- 电话号码：333826752
- 邮箱：iqbal.tariq@riphah.edu.pk
研究联系人备份
- 姓名：Nimra Noor Noor, MS-CPPT
- 电话号码：03030684869
- 邮箱：nimranoor358@gmail.com
学习地点
-
-
Punjab Province
-
Lahore、Punjab Province、巴基斯坦、40100
- Nimra Noor
-
接触：
- Nimra Noor Noor, MS-CPPT
- 电话号码：03030684869
- 邮箱：nimranoor358@gmail.com
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
不
描述
Inclusion Criteria:
- Age group: Middle age adults (40-60 years), medically stable
- Both gender
- Diagnosis based on GOLD criteria ((FEV₁/FVC ratio < 0.70).
- Moderate COPD with no acute exacerbations in the past 4-6 weeks.
- Participants must be able to perform Autogenic drainage and Flutter device physically and mentally.
- Voluntary participation with consent.
Exclusion Criteria:
- Cardic Diseases (Acute MI, Congestive Heart Failure)
- Musculoskeletal Impairements
- Using Non-invasive Ventilation
- Recent lung diseases (Respiratory failure, pneumothorax)
- Hemodynamic instability
- Uncoorperative patients
- Cognitive Impairement scale
- Participants excluded if they did not consent
- Comorbidities affecting exercise tolerance
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Autogenic drainage
The participants in this group will be instructed to sit comfortably with the neck slightly extended and clear the upper airways by huffing or blowing the nose.
Autogenic drainage begins with slow diaphragmatic breathing at low lung volumes, followed by a 3-second pause and gentle high-velocity expiration with an open glottis.
As secretions move upward, breathing gradually shifts to medium and high lung volumes until mucus reaches the trachea for expectoration.
The cycle of breathing exercises is repeated for 15-20 minutes while suppressing unnecessary coughing.
|
The patient begins by performing the diaphragmatic breathing at low lung volume inspiration will slow with a pause of three seconds allowing the collateral ventilation, and expiration will done as a sigh with an open glottis and with high velocity as possible but no forced expiration.
During this low lung volume breathing, expiration will encourage to the expiratory reserve volume.
When the patient feel secretions to be moving, the volume of inspiration became deeper and expiration did not go down as far as expiratory reserve volume.
As the secretions moved up the bronchial tree to the large airways then the patient will ask to perform higher lung volume breathing, tidal volume to inspiratory reserve volume range.
This middle to high lung volume breathing continued until the secretions will in the trachea and ready to be expectorated
其他名称：
|
|
实验性的：Flutter Device (Positive expiratory pressure technique)
The participant in this group will be instructed to sit comfortably while leaning forward with elbows supported and the neck slightly extended to open the airway.
The flutter device is held horizontally with a slight upward tilt and placed in the mouth.
The patient inhales slowly through the nose, holds the breath for 3-5 seconds, and exhales through the flutter device slightly faster than normal.
After 4-8 breaths, a deep inhalation followed by forced expiration through the device helps mobilize secretions.
Breathing control is maintained, followed by coughing or huffing if needed.
The procedure is repeated for 10-15 minutes.
|
The flutter device will hold horizontally and tilted slightly upwards to get maximal oscillatory effect and then it was placed in the mouth.
Inspiration was done through the nose.
A slow breath in, only slightly deeper than normal with a breath hold of 3-5 seconds will followed by breath out through the flutter device at a slightly faster rate than normal.
After 4-8 breaths, a deep breath with a hold' at full inspiration will followed by a force expiration through the flutter device.
This precipitated expectoration and will followed by a pause for breathing control, and then according to the subjects' preference a cough or huff was done
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dyspnea
大体时间：Baseline and after 6 weeks of intervention
|
The modified medical research council; (mMRC) Dyspnea Scale is a simple and widely used scale
|
Baseline and after 6 weeks of intervention
|
|
Forced Vital Capacity
大体时间：Baseline and after 6 weeks of intervention
|
Forced Vital Capacity (FVC) will be measured in liters (L) using spirometry.
FVC represents the maximum volume of air that can be forcefully exhaled after a maximal inspiration.
|
Baseline and after 6 weeks of intervention
|
|
Forced Expiratory Volume in One Second
大体时间：Baseline and after 6 weeks of intervention
|
Forced Expiratory Volume in One Second (FEV₁) will be measured in liters (L) using spirometry.
FEV₁ represents the volume of air exhaled during the first second of a forced expiratory maneuver.
|
Baseline and after 6 weeks of intervention
|
|
FEV₁/FVC ratio
大体时间：Baseline and after 6 weeks of intervention
|
The FEV₁/FVC ratio will be expressed as a percentage (%) and calculated from spirometric measurements to assess the degree of airflow limitation.
|
Baseline and after 6 weeks of intervention
|
|
Peak Expiratory Flow
大体时间：Baseline and after 6 weeks of intervention
|
Peak Expiratory Flow (PEF) will be measured in liters per minute (L/min) and represents the maximum expiratory flow achieved during forced expiration.
|
Baseline and after 6 weeks of intervention
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Arjumand Bano, MS、Riphah International University
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年6月1日
初级完成 (估计的)
2026年8月1日
研究完成 (估计的)
2026年8月1日
研究注册日期
首次提交
2026年6月8日
首先提交符合 QC 标准的
2026年7月17日
首次发布 (实际的)
2026年7月20日
研究记录更新
最后更新发布 (实际的)
2026年7月20日
上次提交的符合 QC 标准的更新
2026年7月17日
最后验证
2026年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.